Abstract

Back to the PAG
Back
Sign In

Similarity in efficacy and safety of abacavir/lamivudine (ABC/3TC) compared to tenofovir/emtricitabine (TDF/FTC) in combination with QD lopinavir/ritonavir (LPV/r) over 96 weeks in the HEAT Study

K.Y. Smith1, D.M. Fine2, P. Patel3, N.C. Bellos4, L. Sloan5, P. Lackey6, P.N. Kumar7, D.H. Sutherland-Phillips3, C. Vavro3, L. Yau3, M.S. Shaefer3

1Rush University Medical Center, Chicago, United States, 2Johns Hopkins University School of Medicine, Baltimore, United States, 3GlaxoSmithKline, Research Triangle Park, United States, 4Southwest Infectious Disease Associates, Dallas, United States, 5North Texas Infectious Disease Consultants, Dallas, United States, 6ID Consultants, Charlotte, United States, 7Georgetown University, Washington, United States

Background: HEAT is the first large, prospective, long-term, head-to-head trial to evaluate the efficacy and safety of these dual NRTI backbones with a boosted PI as part of recommended first-line treatments in HIV-1 infected subjects.
Methods: ART-naive subjects with plasma HIV-1 RNA (VL)
³1000 copies/mL (c/mL), [stratified < or ³100,000 c/mL], and any CD4+ count were randomized to receive ABC/3TC or TDF/FTC with open-label LPV/r QD in this double-blind, placebo-matched, multi-center, 96-week study. Virologic failure (VF) was defined as failure to achieve VL<200 c/mL by Week 24 or confirmed rebound to ³ 200 c/mL. The primary objective at 96 weeks was to evaluate safety and tolerability.
Results: 688 were randomized with mean age of 38 years, 18% female, 49% non-white, baseline median VL 4.87 log10c/mL and CD4+ 202 cells/cmm. Virologic failure occurred in 14% for both groups.

Week 96 Results
ITT-E, M=F, Switch Included Analysis*
ABC/3TC + LPV/r
n=343
TDF/FTC + LPV/r
n=345
95% CI of Difference p-value
VL<50 c/mL*,
BL VL
<100,000 c/mL
BL VL
³100,000 c/mL
60%
63%
56%
58%
58%
58%
(-5.41,9.32)
---
---
0.603
---
---
VL<50 c/mL, TLOVR 52% 51% (-6.33,8.63) 0.763
Median CD4+ (D from BL), cells/cmm 466 (+250) 445 (+247)  
Prematurely Withdrawn due to AEs 20 (18%) 21 (17%)  
Drug-related Grade 3-4 AEs 50 (15%) 52 (15%)  
Drug-related Serious AEs excluding ABC HSR 4 (1%) 6 (2%)  
Suspected ABC HSR 14 (4%) 3 (<1%)  
Proximal Renal Tubule Dysfunction 0 6 (2%)  

Conclusions: These results demonstrate ABC/3TC is virologically noninferior to TDF/FTC when combined with once-daily LPV/r through 96 weeks. Response rates by low and high baseline VL strata were similar in both arms. VF rates and treatment-limiting adverse events were also comparable between arms.



Back - Back to the Programme-at-a-Glance


Copyright Notice © IAS Disclaimer